However, clinical efficacy of anti-PD-1/PD-L1 seems to depend on tumor intrinsic characteristics such as the neoantigen load and the tumor mutational burden [16,17]; hence, it is essential to investigate possible mechanisms through which the tumor can escape or antagonize the immunotherapeutic efficacy of these mAbs. Here, CD274 is linked to neoplasm.